Brii Biosciences Limited

SEHK:2137 Stock Report

Market Cap: HK$1.1b

Brii Biosciences Past Earnings Performance

Past criteria checks 0/6

Brii Biosciences has been growing earnings at an average annual rate of 41.3%, while the Biotechs industry saw earnings growing at 31.7% annually. Revenues have been declining at an average rate of 15.3% per year.

Key information

41.3%

Earnings growth rate

60.6%

EPS growth rate

Biotechs Industry Growth11.0%
Revenue growth rate-15.3%
Return on equity-9.6%
Net Margin-691.6%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Brii Biosciences (HKG:2137) Is In A Good Position To Deliver On Growth Plans

Nov 19
Brii Biosciences (HKG:2137) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not Too Worried About Brii Biosciences' (HKG:2137) Cash Burn Situation

Jul 26
Here's Why We're Not Too Worried About Brii Biosciences' (HKG:2137) Cash Burn Situation

Companies Like Brii Biosciences (HKG:2137) Are In A Position To Invest In Growth

Jan 12
Companies Like Brii Biosciences (HKG:2137) Are In A Position To Invest In Growth

We're Hopeful That Brii Biosciences (HKG:2137) Will Use Its Cash Wisely

Sep 20
We're Hopeful That Brii Biosciences (HKG:2137) Will Use Its Cash Wisely

We're Not Worried About Brii Biosciences' (HKG:2137) Cash Burn

Mar 24
We're Not Worried About Brii Biosciences' (HKG:2137) Cash Burn

Revenue & Expenses Breakdown

How Brii Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SEHK:2137 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2438-265205327
31 Mar 2447-220202365
31 Dec 2356-175198403
30 Sep 2395-251193394
30 Jun 23134-327189384
31 Mar 23128-405192412
31 Dec 22122-484195441
30 Sep 2299-1,021223518
30 Jun 2275-1,558251595
31 Mar 2284-2,861230545
31 Dec 2193-4,164208495
30 Sep 21100-3,999169631
30 Jun 21107-3,835130768
31 Mar 2194-2,512117822
31 Dec 2082-1,190103876
31 Dec 1920-5216384

Quality Earnings: 2137 is currently unprofitable.

Growing Profit Margin: 2137 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 2137 is unprofitable, but has reduced losses over the past 5 years at a rate of 41.3% per year.

Accelerating Growth: Unable to compare 2137's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 2137 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (14.3%).


Return on Equity

High ROE: 2137 has a negative Return on Equity (-9.64%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies